Company / Operating Income
RAPT Therapeutics, Inc. Operating Income History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$136.1M
FY2024
5-year range
-$136.1M / -$53.2M
FY2020-FY2024
Trend
-7.1%
vs FY2023
Sector context
#108 of 202
Health Care
What the data says
At -$136M, RAPT Therapeutics, Inc.'s operating income ranks #108 of 202 in the Health Care sector. Operating Income has declined for 6 consecutive years, from -$37M in FY2018 to -$136M in FY2024.
Based on SEC 10-K filings.
-$136M in FY2024.
Declined from -$86M to -$136M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#108 of 202 in Health CareTop 53% of 202This company -$136.1M Sector average $70.7M
▼
-292.5% below sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s operating income has declined for 6 consecutive years.
- In FY2024, operating income decreased 7.1% year-over-year.
- Ranks #108 out of 202 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$136.1M | -7.1% |
| FY2023 | -$127.1M | -48.1% |
| FY2022 | -$85.8M | -24.0% |
| FY2021 | -$69.2M | -30.1% |
| FY2020 | -$53.2M | -22.0% |
| FY2019 | -$43.6M | -18.1% |
| FY2018 | -$36.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026